41472-49-5

Basic information

• Product Name: N-(P-SULFAMOYLPHENETHYL)ACETAMIDE
• Synonyms: N-ACETYL-4-(2-AMINOETHYL)-BENZENESULFONAMIDE;N-ACETYL (2-AMINOETHYL)BENZENE SULPHONAMIDE;N-(P-SULFAMOYLPHENETHYL)ACETAMIDE;4-(2-acetylaminoethyl)benzenesulfonamide;N-[2-[4-(aminosulphonyl)phenyl]ethyl]acetamide;4-[2-(N-Acetylamino)-ethyl]-benzenesulfonamide;4-[N-Acetyl-2-(aminoethyl)]benzenesulphonamide 96%;N-[2-(4-Sulphamoylphenyl)ethyl]acetamide
• CAS NO: 41472-49-5
• Molecular Formula: C₁₀H₁₄N₂O₃S
• Molecular Weight: 242.29
• EINECS: 255-386-5
• Mol File: 41472-49-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 168-174°C
• Boiling Point: 387.4°C at 760 mmHg
• Flash Point: 188.1°C
• Appearance: /
• Density: 1.274 g/cm³
• Vapor Pressure: 3.31E-06mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 10.16±0.10(Predicted)
• CAS DataBase Reference: N-(P-SULFAMOYLPHENETHYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(P-SULFAMOYLPHENETHYL)ACETAMIDE(41472-49-5)
• EPA Substance Registry System: N-(P-SULFAMOYLPHENETHYL)ACETAMIDE(41472-49-5)

Safety Data

• Hazardous Substances Data: 41472-49-5(Hazardous Substances Data)

Usage

Description

N-(P-SULFAMOYLPHENETHYL)ACETAMIDE, also known as N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-acetamide, is a chemical compound with a unique structure that features a sulfonylurea or thiourea derivative substituted with benzenesulfonamide groups. N-(P-SULFAMOYLPHENETHYL)ACETAMIDE has potential applications in the pharmaceutical industry due to its specific properties and reactivity.

Uses

Used in Pharmaceutical Industry:
N-(P-SULFAMOYLPHENETHYL)ACETAMIDE is used as a key intermediate in the synthesis of sulfonylurea and thiourea derivatives. These derivatives are of significant interest due to their potential as hypoglycemic agents, which can be used in the treatment of diabetes mellitus. N-(P-SULFAMOYLPHENETHYL)ACETAMIDE's ability to form derivatives with hypoglycemic properties makes it a valuable asset in the development of new drugs for managing blood sugar levels in diabetic patients.

InChI:InChI=1/C8H12N2O2S.ClH/c9-6-5-7-1-3-8(4-2-7)13(10,11)12;/h1-4H,5-6,9H2,(H2,10,11,12);1H

Upstream product

• 35450-53-4 sulfonyl chloride 
• 108-24-7 acetic anhydride 
• 35303-76-5 4-(2-aminoethyl)benzenesulfonamide 
• 877-95-2 methyl-N-(benzyl-methyl)-formamide 
• 64-04-0 phenethylamine 
• 75-36-5 acetyl chloride 

Downstream Products

• 35303-76-5 4-(2-aminoethyl)benzenesulfonamide 
• 2191-62-0 C₁₇H₂₅N₃O₄S 
• 2015-16-9 N-(4-[2-amino-ethyl]-benzenesulfonyl)-N'-cyclohexyl urea 
• 88759-61-9 C₂₅H₃₂N₄O₆S 
• 88759-65-3 C₂₈H₃₈N₄O₆S 
• 88759-67-5 C₂₉H₄₀N₄O₆S 
• 88759-69-7 C₃₂H₃₈N₄O₆S 
• 88759-63-1 1-cyclohexyl-3-<4-(β-benzyloxycarbonylalanylaminoethyl)phenylsulfonyl>urea 
• 88759-71-1 C₂₆H₃₄N₄O₆S 

Relevant articles and documents

Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator

To optimize the lead urea scaffold 1 and 2 as selective cardiac myosin ATPase activator, a series of urea derivatives have been synthesized to explore its structure activity relationship. Among them N,N-dimethyl-4-(2-(3-(3-phenylpropyl)ureido)ethyl)benzenesulfonamide (13, CMA = 91.6%, FS = 17.62%; EF = 11.55%), N,N-dimethyl-4-(2-(1-methyl-3-(3-phenylpropyl)ureido)ethyl)benzene sulfonamide (40, CMA = 52.3%, FS = 38.96%; EF = 24.19%) and N,N-dimethyl-4-(2-(3-methyl-3-(3-phenylpropyl)ureido)ethyl)benzenesulfonamide (41, CMA = 47.6%, FS = 23.19%; EF = 15.47%) proved to be efficient to activate the cardiac myosin in vitro and in vivo. Further the % change in ventricular cell contractility at 5 μM of 13 (47.9 ± 3.2), 40 (45.5 ± 2.4) and 41 (63.5 ± 2.2) showed positive inotropic effect in isolated rat ventricular myocytes. The potent compounds 13, 40, 41 were highly selective for cardiac myosin over skeletal and smooth muscle myosin, thus proving them these new urea derivatives is a novel scaffold for discovery of cardiac myosin activators for the treatment of systolic heart failure.

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016